June 2, 2018
milestone

Major Milestones In Cancer Research

Research and development within the cancer field is continuously evolving and progressing. This video highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the […]
April 26, 2018
oxford_global

5th Biennial Biosimilars & Biobetters Congress, London

Last week London had a pretty good weather, slightly chilly evenings and surprisingly, sun-kissed mornings! Yes, we were there to attend the 5th Biennial Biosimilars & Biobetters Congress in London (since the event was in London. I guess it’s a mandate to start with a weather update J) It was […]
May 31, 2017

Glioblastoma Multiforme Abstracts – RAS Viewpoint

An aggressive malignancy, Glioblastoma is an indication with one of the highest level of unmet need in oncology. Currently, Avastin and Temozolomide dominates the market.  With GBM market estimated to reach $3.3B (G7 market) by 2024 (Globaldata), companies are trying out novel approaches. GBM pipeline is characterized by active early […]
May 28, 2017

CRC Abstracts – RAS Viewpoint

At ASCO 2017, the steadily increasing competitive intensity between Lonsurf (TAS-102, Taiho) and Stivarga (regorafenib, Bayer) will be on display . In addition, the I/O agents are reading out both as monotherapy in specific (dMMR/MSI-H) patient segments, as well as in combinations with other cytotoxic and targeted agents in broader patient […]
May 22, 2017

Future of Cancer Care 2030 – RAS Viewpoint

There are four areas of innovation that are noticeable both in isolation and how they feed into each other for a transformation in cancer care “Big data” and Bioinformatics – rapidly developing data management systems and analytics e.g. NGS that will enable us to collect, analyze and learn from vast amounts […]
May 18, 2017

The Clot War Continues

For more than half a century, patients with Non-Valvular Atrial Fibrillation (NVAF) have been using vitamin K antagonist (Warfarin) to prevent stroke and thromboembolism. Warfarin has proved to be effective, however, it comes with its own baggage of side effects. The use of warfarin is limited due to risk of […]